€ million |
|
Note |
|
2025 |
|
2024 |
||||
|---|---|---|---|---|---|---|---|---|---|---|
Net sales |
|
|
21,102 |
|
21,156 |
|||||
Cost of sales |
|
|
-8,756 |
|
-8,671 |
|||||
Gross profit |
|
|
|
12,346 |
|
12,485 |
||||
|
|
|
|
|
|
|
||||
Marketing and selling expenses |
|
|
-4,562 |
|
-4,536 |
|||||
Administration expenses |
|
|
|
-1,437 |
|
-1,370 |
||||
Research and development costs |
|
|
-2,415 |
|
-2,279 |
|||||
Impairment losses and reversals of impairment losses on financial assets (net) |
|
|
15 |
|
-8 |
|||||
Other operating income |
|
|
734 |
|
269 |
|||||
Other operating expenses |
|
|
-1,081 |
|
-915 |
|||||
Operating result (EBIT)1 |
|
|
|
3,601 |
|
3,645 |
||||
|
|
|
|
|
|
|
||||
Financial income |
|
|
111 |
|
200 |
|||||
Financial expenses |
|
|
-404 |
|
-309 |
|||||
Profit before income tax |
|
|
|
3,308 |
|
3,536 |
||||
|
|
|
|
|
|
|
||||
Income tax |
|
|
-693 |
|
-751 |
|||||
Profit after tax |
|
|
|
2,615 |
|
2,786 |
||||
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany (net income) |
|
|
|
2,608 |
|
2,777 |
||||
thereof: attributable to non-controlling interests |
|
|
7 |
|
9 |
|||||
|
|
|
|
|
|
|
||||
Earnings per share (in €) |
|
|
|
|
|
|||||
Basic |
|
|
|
6.00 |
|
6.39 |
||||
Diluted |
|
|
|
6.00 |
|
6.39 |
||||
|
||||||||||
